Author | Country of traveler | Country of travel | Population | Study design | Antibiotic evaluated | Dose and frequency | No. of patientsin allregimens | Duration of therapy | Protective Efficacy |
---|---|---|---|---|---|---|---|---|---|
Studies reviewed and included in meta-analysis | |||||||||
Johnson et al. (1986) [24] | USA | Mexico | Language school | R, DB, PC | Norfloxacin | 400 mg daily | 115 | 14 days | 88%* |
Wistrom et al. (1987) [31] | Sweden | Africa, Asia, South America | NS | R, DB, PC | Norfloxacin | 200 mg bid | 115 | 5 to 21 days | 84%* |
Scott et al. (1990) [34] | USA/ Italy | Egypt | Military | R, DB, PC | Norfloxacin | 400 mg daily | 222 | 7 days | 93%* |
Rademaker et al. (1989) [30] | The Netherlands | Tunisia | Leisure | R, DB, PC | Ciprofloxacin | 500 mg daily | 53 | 8 days | 94%* |
Heck et al. (1994) [33] | USA | Central and South America | Volunteering | R, DB, PC | Ciprofloxacin | 500 mg daily | 278 | 5 to14 days | 85%* |
DuPont et al. (2005) [26] | USA | Mexico | Language school | R, DB, PC | Rifaximin | 200 mg daily, bid, tid | 210 | 14 days | 73%*,a |
Armstrong et al. (2010) [25] | USA | Turkey | Military | R, DB, PC | Rifaximin | 1,100 mg daily | 95 | 14 days | 67% |
Martinez-Sandoval et al. (2010) [28] | USA | Mexico | Language school | R, DB, PC | Rifaximin | 600 mg daily | 201 | 14 days | 68%* |
Flores et al. (2011) [27] | USA | Mexico | Language school | R, DB, PC | Rifaximin | 550 mg daily | 98 | 14 days | 28% |
Other studies of relevance reviewed but not included in meta-analysis | |||||||||
Parry et al. (1994) [29] | UK | Nepal | Himalayan expedition | R, DB, PC | Ciprofloxacin | 250 mg daily | 21 | 28 days | NA |
Taylor et al. (2006) [32] | NA | NA | Volunteers | R, DB, PC | Rifaximin | 200 mg tid | 25 | 3 days | NA |